These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30288088)

  • 1. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice.
    Ho KY; Gwee KA; Cheng YK; Yoon KH; Hee HT; Omar AR
    J Pain Res; 2018; 11():1937-1948. PubMed ID: 30288088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice Advisory on the Appropriate Use of NSAIDs in Primary Care.
    Ho KY; Cardosa MS; Chaiamnuay S; Hidayat R; Ho HQT; Kamil O; Mokhtar SA; Nakata K; Navarra SV; Nguyen VH; Pinzon R; Tsuruoka S; Yim HB; Choy E
    J Pain Res; 2020; 13():1925-1939. PubMed ID: 32821151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
    Niculescu L; Li C; Huang J; Mallen S
    Curr Med Res Opin; 2009 Mar; 25(3):729-40. PubMed ID: 19210159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
    Minhas D; Nidhaan A; Husni ME
    Rheum Dis Clin North Am; 2023 Feb; 49(1):179-191. PubMed ID: 36424024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of celecoxib versus traditional nonsteroidal anti-inflammatory drugs in older patients with arthritis.
    Shin S
    J Pain Res; 2018; 11():3211-3219. PubMed ID: 30588073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal and cardiovascular adverse events associated with NSAIDs.
    Domper Arnal MJ; Hijos-Mallada G; Lanas A
    Expert Opin Drug Saf; 2022 Mar; 21(3):373-384. PubMed ID: 34376069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and Treatment of NSAID Gastropathy.
    Gargallo CJ; Sostres C; Lanas A
    Curr Treat Options Gastroenterol; 2014 Dec; 12(4):398-413. PubMed ID: 25209136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
    Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
    Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.
    Scarpignato C; Lanas A; Blandizzi C; Lems WF; Hermann M; Hunt RH;
    BMC Med; 2015 Mar; 13():55. PubMed ID: 25857826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.